178 related articles for article (PubMed ID: 37424279)
1.
Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
3. The role of
Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
[TBL] [Abstract][Full Text] [Related]
4. Combining the radiomic features and traditional parameters of
Chen YH; Lue KH; Chu SC; Chang BS; Wang LY; Liu DW; Liu SH; Chao YK; Chan SC
Ann Nucl Med; 2019 Sep; 33(9):657-670. PubMed ID: 31218571
[TBL] [Abstract][Full Text] [Related]
5. Use of
Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
[TBL] [Abstract][Full Text] [Related]
6. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
7. Role of
Sasaki K; Uchikado Y; Okumura H; Omoto I; Kita Y; Arigami T; Uenosono Y; Owaki T; Maemura K; Natsugoe S
Anticancer Res; 2017 Feb; 37(2):859-864. PubMed ID: 28179343
[TBL] [Abstract][Full Text] [Related]
8. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Yang Y; Yi Y; Wang Z; Li S; Zhang B; Sang Z; Zhang L; Cao Q; Li B
BMC Cancer; 2024 Apr; 24(1):460. PubMed ID: 38609892
[TBL] [Abstract][Full Text] [Related]
9. Association between prognosis and lymph node status using
Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
World J Surg; 2024 Mar; 48(3):650-661. PubMed ID: 38686781
[TBL] [Abstract][Full Text] [Related]
10. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [
Dong Y; Wei Y; Chen G; Huang Y; Song P; Liu S; Zheng J; Cheng M; Yuan S
Mol Imaging Biol; 2019 Feb; 21(1):175-182. PubMed ID: 29869060
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of
Yin X; Li J; Chen B; Liu K; Hu S
Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538
[TBL] [Abstract][Full Text] [Related]
13. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
14. Tumor SUVs on 18F-FDG PET/CT and Aggressive Pathological Features in Esophageal Squamous Cell Carcinoma.
Lim CH; Park YJ; Shin M; Cho YS; Choi JY; Lee KH; Hyun SH
Clin Nucl Med; 2020 Mar; 45(3):e128-e133. PubMed ID: 31977480
[TBL] [Abstract][Full Text] [Related]
15. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
[TBL] [Abstract][Full Text] [Related]
16. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma.
Toriyama K; Tajika M; Tanaka T; Ishihara M; Hirayama Y; Onishi S; Mizuno N; Kuwahara T; Okuno N; Matsumoto S; Sasaki E; Abe T; Yatabe Y; Hara K; Matsuo K; Tamaki T; Niwa Y
World J Gastroenterol; 2019 Dec; 25(46):6767-6780. PubMed ID: 31857778
[TBL] [Abstract][Full Text] [Related]
19. Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus.
Sonoda A; Yoshida N; Shiraishi S; Horinouchi T; Tokunaga R; Harada K; Iwatsuki M; Nagai Y; Baba Y; Iwagami S; Miyamoto Y; Baba H
Ann Surg Oncol; 2021 Jan; 28(1):167-174. PubMed ID: 32588261
[TBL] [Abstract][Full Text] [Related]
20. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
